Dietary Milk-Fat-Globule Membrane Affects Resistance to Diarrheagenic Escherichia coli in Healthy Adults in a Randomized, Placebo-Controlled, Double-Blind Study

AbstractWe conducted a randomised, double-blind, placebo-controlled trial to elucidate the effects of dietary milk fat globule membrane (MFGM) on the physical performance of community-dwelling Japanese adults. For this 24-week study, 115 middle-aged subjects (range 50–70 years old) were invited, of whom 113 (seventy-two women, forty-one men) completed the trial. Participants were then divided into either the placebo control or MFGM group. Measurements of physical performance (without undertaking any mandatory exercise) examining muscle strength, agility and balance were tested every 6 weeks until 24 weeks. Analyses were performed using the intention-to-treat method for all participants. Although the effects of MFGM on muscle strength and agility were not significant, we noted that the parameter for balance (such as the ability to stand on one leg with eyes closed for longer durations) increased in the MFGM group (mean 10·1 (95 % CI 8·25, 12·4) s) compared with the placebo (mean 7·53 (95 % CI 6·11, 9·30) s) (P = 0·046). Similarly, application of the mixed-effect model for repeated measures under unstructured covariance also revealed that the effect of MFGM was significant when compared with the placebo (10·2 (95 % CI 8·33, 12·4) v. 7·61 (95 % CI 6·17, 9·30) s) (P = 0·045). In conclusion, we demonstrated that MFGM had an effect on the physical performance of community-dwelling Japanese adults despite mandatory exercise. However, studies using larger cohorts of individuals from different demographic backgrounds are required to further elucidate the mechanisms underlying these effects and to extend the application of MFGM.

Download Full-text

Bovine milk fat globule membrane affects virulence expression in Escherichia coli O157:H7

Journal of Dairy Science ◽

10.3168/jds.2012-5560 ◽

2012 ◽

Vol 95 (11) ◽

pp. 6313-6319 ◽

Cited By ~ 17

Author(s):

A. Tellez ◽

M. Corredig ◽

A. Guri ◽

R. Zanabria ◽

M.W. Griffiths ◽

...

Keyword(s):

Escherichia Coli ◽

Milk Fat ◽

Bovine Milk ◽

Escherichia Coli O157 ◽

Milk Fat Globule Membrane ◽

Expression In Escherichia Coli ◽

Milk Fat Globule ◽

Fat Globule

Download Full-text

Alleviation of Metabolic Endotoxemia by Milk Fat Globule Membrane: Rationale, Design, and Methods of a Double-Blind, Randomized, Controlled, Crossover Dietary Intervention in Adults with Metabolic Syndrome

Current Developments in Nutrition ◽

10.1093/cdn/nzaa130 ◽

2020 ◽

Vol 4 (9) ◽

Author(s):

William R Quarles ◽

Avi Pokala ◽

Emily L Shaw ◽

Joana Ortega-Anaya ◽

Lisa Hillmann ◽

...

Keyword(s):

Metabolic Syndrome ◽

Milk Fat ◽

Cardiometabolic Risk ◽

Inflammatory Responses ◽

Gut Permeability ◽

Double Blind ◽

Barrier Functions ◽

Milk Fat Globule Membrane ◽

Milk Fat Globule ◽

Fat Globule

ABSTRACT Background Milk fat globule membrane (MFGM) is a phospholipid-rich component of dairy fat that might explain the benefits of full-fat dairy products on cardiometabolic risk. Preclinical studies support that MFGM decreases gut permeability, which could attenuate gut-derived endotoxin translocation and consequent inflammatory responses that impair cardiometabolic health. Objectives To describe the rationale, study design, and planned outcomes that will evaluate the efficacy of MFGM-enriched milk compared with a comparator beverage on health-promoting gut barrier functions in persons with metabolic syndrome (MetS). Methods We plan a double-blind, randomized, crossover trial in which people with MetS will receive a rigorously controlled eucaloric diet for 2 wk that contains 3 daily servings of an MFGM-enriched bovine milk beverage or a comparator beverage that is formulated with nonfat dairy powder, coconut and palm oils, and soy phospholipids. Compliance will be monitored by assessing urinary para-aminobenzoic acid that is added to all test beverages. After the intervention, participants will ingest a high-fat/high-carbohydrate meal challenge to assess metabolic excursions at 30-min intervals for 3 h. Nondigestible sugar probes also will be ingested prior to collecting 24-h urine to assess region-specific gut permeability. Intervention efficacy will be determined based on circulating endotoxin (primary outcome) and glycemia (secondary outcome). Tertiary outcomes include: gut and systemic inflammatory responses, microbiota composition and SCFAs, gut permeability, and circulating insulin and incretins. Expected results MFGM is expected to decrease circulating endotoxin and glycemia without altering body mass. These improvements are anticipated to be accompanied by decreased gut permeability, decreased intestinal and circulating biomarkers of inflammation, increased circulating incretins, and beneficial antimicrobial and prebiotic effects in the gut microbiome. Conclusions Demonstration of improvements in gut barrier functions that limit endotoxemia and glycemia could help to establish direct evidence that full-fat dairy lowers cardiometabolic risk, especially in people with MetS. The clinical trial associated with this article has been registered at clinicaltrials.gov (NCT03860584).

Download Full-text

Supplementation with milk enriched with complex lipids during pregnancy: A double-blind randomized controlled trial

PLoS ONE ◽

10.1371/journal.pone.0244916 ◽

2021 ◽

Vol 16 (2) ◽

pp. e0244916

Author(s):

Benjamin B. Albert ◽

José G. B. Derraik ◽

Yin-Yin Xia ◽

Tom Norris ◽

Ting Zhang ◽

...

Keyword(s):

Clinical Trial ◽

Milk Fat ◽

Reference Group ◽

Controlled Trial ◽

Double Blind ◽

Milk Fat Globule Membrane ◽

Randomized Controlled ◽

Milk Fat Globule ◽

Fat Globule ◽

Enriched Milk

Background Gangliosides are a class of sphingolipids that are present in the cell membranes of vertebrates. Gangliosides influence a broad range of cellular processes through effects on signal transduction, being found abundantly in the brain, and having a role in neurodevelopment. Objective We aimed to assess the effects of maternal daily consumption of ganglioside-enriched milk vs non-enriched milk and a non-supplemented group of pregnant women on maternal ganglioside levels and pregnancy outcomes. Design Double-blind parallel randomized controlled trial. Methods 1,500 women aged 20–40 years were recruited in Chongqing (China) between 11 and 14 weeks of a singleton pregnancy, and randomized into three groups: Control–received standard powdered milk formulation (≥4 mg gangliosides/day); Complex milk lipid-enhanced (CML-E) group–same formulation enriched with complex milk lipids (≥8 mg gangliosides/day) from milk fat globule membrane; Reference–received no milk. Serum ganglioside levels were measured in a randomly selected subsample of 250 women per group. Results CML-E milk was associated with marginally greater total gangliosides levels in maternal serum compared to Control (13.02 vs 12.69 μg/ml; p = 0.034) but not to Reference group. CML-E milk did not affect cord blood ganglioside levels. Among the 1500 women, CML-E milk consumption was associated with a lower rate of gestational diabetes mellitus than control milk [relative risk 0.80 (95% CI 0.64, 0.99)], but which was not different to the Reference group. CML-E milk supplementation had no other effects on maternal or newborn health. Conclusions Maternal supplementation with milk fat globule membrane, as a source of gangliosides, was not associated with any adverse health outcomes, and did not increase serum gangliosides compared with the non-supplemented reference group. Trial registration Chinese Clinical Trial Register (ChiCTR-IOR-16007700). Clinical trial registration ChiCTR-IOR-16007700; www.chictr.org.cn/showprojen.aspx?proj=12972.

Download Full-text